Among the multiple drugs targeting the Hippo pathway, YAP/TAZ/TEAD and their regulators, TEAD inhibitors appear to emerge as the most effective and potent suppressors of YAP/TAZ-driven cancer growth, because TEADs bind YAP/TAZ directly and, hence, are the most downstream effectors of the pathway. Here, YAP1 is linked to cancer.